ClinicalTrials.gg
RecruitingNCT04914234Updated Sep 21, 2026

Premedication With Atenolol Versus Metoprolol for Controlled Hypotensive Anesthesia During Nasal Surgeries

A Phase 4 interventional study of Atenolol Succinate Oral Tablet and Metoprolol Succinate Oral Tablet in Hypotension Drug-Induced, sponsored by Damanhour Teaching Hospital. Recruiting at 1 site in Egypt. Open to participants aged 21 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Damanhour Teaching Hospital · Phase 4, Interventional, and Prevention

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
21 Years to 50 Years
Sex
All
01

Study summary

Objectives: To compare the safety and efficacy of oral atenolol versus oral metoprolol as a premedication for controlled hypotensive anesthesia during nasal surgeries.

Background: Mucosal bleeding is the most frequent complication with nasal surgeries, as it interferes with the optimal visualization of the intranasal anatomy, increases operation time, and consequently increases blood loss. There are several pharmacological and non-pharmacological techniques for the appropriate control of intraoperative bleeding.

Patients and Methods: This was a prospective, randomized, double-blind, phase four, comparative clinical trial; carried out on 60 patients, who were candidates for nasal surgeries under general anesthesia at our hospital. Patients were randomly allocated into two equal groups; group A, received oral atenolol, and group M, received oral metoprolol.

02

Conditions studied

  • Hypotension Drug-Induced

Browse trials for

Keywords

  • atenolol
  • controlled hypotension
  • metoprolol
  • nasal surgery
03

In context

Hypotension

885 studies on the registry are indexed under Hypotension; 195 are open to participants now.

This study's planned enrollment of 60 is below the median of 87 across 590 interventional studies indexed under Hypotension.

Browse Hypotension studies →

Lead sponsor

Damanhour Teaching Hospital is the lead sponsor of 14 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ASA) physical status ≤ II
  • Age from 21 to 50 years

Exclusion criteria

Exclusion Criteria:

  • > II
  • Age \< 21 years or > 50 years
  • Pregnant women
  • Breastfeeding
  • Bronchial asthma
  • Diabetes Mellitus
  • Hypertension
  • Ischemic heart disease
  • Rheumatic heart disease
  • Heart failure
  • Heart block
  • Sick sinus syndrome
  • Sinus bradycardia
  • Chronic hypotension
  • Anemia ( \< 10 g/dl)
  • Renal or hepatic dysfunction
  • Central nervous system disease
  • Allergic fungal sinusitis
  • Patients on beta-blockers
  • Alcohol or drug abuse
  • Anticoagulation therapy,
  • Bleeding diathesis
  • Agents influencing autonomic nervous system
  • Allergy to the study drugs
  • Any of oral intake
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Group A (n=30)

    Atenolol group

    Drug: Atenolol Succinate Oral Tablet

  • Active comparator
    Group M (n=30)

    Metoprolol group

    Drug: Metoprolol Succinate Oral Tablet

Interventions

  • DrugAtenolol Succinate Oral Tablet

    Atenolol 50 mg

    Also known as: Tenormin tablets

  • Metoprolol 100 mg

    Also known as: Seloken ZOC tablets

06

What researchers measure

Primary outcomes

  1. Mean and Standard deviation of Blood loss (ml)(mean±SD)

    Amount of blood loss at the end of surgery

    Time frame: 5 minutes after the end of surgery

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04914234
Lead sponsor
Damanhour Teaching Hospital
Responsible party
Sponsor
First posted
Jun 4, 2021
Start date
Dec 1, 2025
Primary completion
Jan 15, 2027 (estimated)
Completion
Jan 30, 2027 (estimated)
Last update
Sep 21, 2026

Study contacts

Ahmed M Shaat, MD
Contact
ahmedshaat99@gmail.com
00201223482709
Ahmed M Shaat, MD
principal investigator · Damanhour Teaching Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metoprolol

Start the discussion